Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRLX101 + mFOLFOX6
- Development stage
- Unknown
- Lead developer
- Daré Bioscience
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
CRLX101 + mFOLFOX6 is a combination of a nanopharmaceutical polymer-drug conjugate (CRLX101) and a modified FOLFOX6 chemotherapy regimen. - **CRLX101** is a nanoparticle-based polymer conjugate containing camptothecin, a topoisomerase I inhibitor. It is designed to improve drug delivery, prolong drug exposure, and reduce toxicity by slowly releasing camptothecin from its nanoparticle matrix. CRLX101 inhibits both topoisomerase I and hypoxia-inducible factor 1-alpha (HIF-1α), leading to anti-tumor effects. - **mFOLFOX6** is a chemotherapy regimen consisting of **oxaliplatin (a platinum-based DNA crosslinking agent), leucovorin (folinic acid), and fluorouracil (5-FU, a thymidylate synthase inhibitor)** given intravenously[1][2][5][6]. mFOLFOX6 is a modified version of FOLFOX, commonly used for colorectal cancer and, in research settings, combined with investigational agents such as CRLX101 for advanced gastrointestinal malignancy.
- Other names
- CRLX101CRLX-101CRLX 101mFOLFOX6mFOLFOX-6mFOLFOX 6CRLX101 plus modified FOLFOX6CRLX-101 plus modified FOLFOX6CRLX 101 plus modified FOLFOX6
02
Targets
TOP1 (DNA Topoisomerase I)HIF1A (Hypoxia-inducible factor 1-alpha)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on CRLX101 + mFOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRLX101 + mFOLFOX6.